Taylor, your album should be'Life of a Callgirl'. KENNEDY's appalled take on Swift's new record... and its ultra-vivid sex shout outs for Travis the Sasquatch The truth about Keith Urban's guitarist'other woman' Maggie Baugh revealed amid Nicole Kidman divorce How I look like this at 62. I've lost 5 stone fast, 20 years off my biological age and wear size 8... without weight-loss jabs. My war with Harry & Meghan, by PIERS MORGAN: What really happened, their absurd accusations, the brutal truth about post-royal life... and how I believe their royal racism lies helped kill off woke Shroud of Turin mystery deepens as surgeon spots hidden detail that points to Jesus' resurrection I'm no longer sleeping with my husband - and never will again, says MOLLY RYDDELL. I love him, but counted down the moments until he climaxed. Then I couldn't bear it any more and the truth spilled out... so many women feel the same Fans erupt at Taylor Swift's'dig' at Travis Kelce's ex Kayla Nicole in wild The Life of a Showgirl track Trump dollar coin design released by Treasury... and it's inspired by an iconic political photo The THREE singers Keith Urban's been cosying up to revealed - now Nicole Kidman's on the warpath and has done the thing every estranged husband fears most: ALISON BOSHOFF Lori Loughlin's husband Mossimo Giannulli seen with mystery brunette in tiny skirt day after shock split Trump appears alongside Melania at dinner hosted by JD Vance and Usha after'disappearance' rumors Top plastic surgeons reveal secrets behind Taylor Swift's'changing' face: 'It is looking very full' I'm a woman with autism... here are the signs you might be masking, even from yourself Cake-faced 90s sitcom star looks unrecognizable as she ditches the heavy eyeshadow for an LA errand run can you guess who?

There was a time when the little robot dog was among the most coveted items in the world. From about 1999 to 2008, all kids had to do was decide which little robot dog they longed for the most. There were so many fantastic options. From the Canadian company WowWee, Mega-Byte the Hound Droid, which had a big, blocky head and glowing eyes. From Mattel, Rocket the Wonder Dog, which "rocketed through space, time, and the Milky-Bone Galaxy looking for a loving home here on earth."

The anthropologist and famed love expert Helen Fisher seemed ready to dash into oncoming traffic. We were on a sidewalk in Manhattan, opposite the American Museum of Natural History, and nowhere near a safe place to cross the street. She wanted me to stare down the yellow cabs and charge off the curb, though she knew I wouldn't do it: I'd recently taken the personality questionnaire she wrote 17 years ago for a dating website, which produced the insight that I am a cautious, conventional rule follower. She, however, is an "explorer"--she has visited 111 countries, including North Korea--but also, being high in estrogen, a "negotiator" who will use the crosswalk for my benefit. "I am horribly empathetic," she told me. I look into baby carriages and worry about their future with love." This is how Fisher, the 77-year-old chief scientific adviser for Match.com and one of the best-known, most-often-quoted experts on romance and "mate choice," understands life: Personality is a cocktail of ...

Deep neural networks (DNNs) and decision trees (DTs) are both state-of-the-art classifiers. DNNs perform well due to their representational learning capabilities, while DTs are computationally efficient as they perform inference along one route (root-to-leaf) that is dependent on the input data. In this paper, we present DecisioNet (DN), a binary-tree structured neural network. We propose a systematic way to convert an existing DNN into a DN to create a lightweight version of the original model. DecisioNet takes the best of both worlds - it uses neural modules to perform representational learning and utilizes its tree structure to perform only a portion of the computations. We evaluate various DN architectures, along with their corresponding baseline models on the FashionMNIST, CIFAR10, and CIFAR100 datasets. We show that the DN variants achieve similar accuracy while significantly reducing the computational cost of the original network.

There is a common misconception that once AI becomes embedded in healthcare processes, it will take away human jobs. That scenario is unlikely to occur, however, because AI's true role is to aggregate and analyze reams of data. That task is difficult for humans, so AI will be a welcome partner in clinical decision-making. This stance is supported by Scott Gottlieb, former commissioner at the Food and Drug Administration (FDA) and now a board member at Pfizer and Illumina. He is also a senior fellow at the American Enterprise Institute, a public policy firm.

Tempus, a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare, today announced that Dr. Scott Gottlieb, MD, has joined its Board of Directors. Dr. Gottlieb will serve as an advisor to Tempus and its leadership team, leveraging his vast experience as a medical policy expert and public health advocate to support Tempus as it harnesses the power and promise of big data and artificial intelligence to personalize patient care. Dr. Gottlieb most recently served as the 23rd Commissioner of the Food and Drug Administration (FDA), where he focused on developing innovative approaches to improving medical outcomes, reshaping healthcare delivery, and expanding patient choice and safety. Previously, he also served as the agency's Deputy Commissioner for Medical and Scientific Affairs and as a Senior Advisor to the FDA Commissioner. During his time as a Senior Advisor to the Administrator of the Centers for Medicare and Medicaid Services, Dr. Gottlieb worked on the implementation of the Medicare drug benefit, where he supported policy work on quality improvement and the agency's coverage process, particularly as it related to new medical technologies.

The Food and Drug Administration announced Tuesday that it is developing a framework for regulating artificial intelligence products used in medicine that continually adapt based on new data. The agency's outgoing commissioner, Scott Gottlieb, released a white paper that sets forth the broad outlines of the FDA's proposed approach to establishing greater oversight over this rapidly evolving segment of AI products. It is the most forceful step the FDA has taken to assert the need to regulate a category of artificial intelligence systems whose performance constantly changes based on exposure to new patients and data in clinical settings. These machine-learning systems present a particularly thorny problem for the FDA, because the agency is essentially trying to hit a moving target in regulating them. The white paper describes criteria the agency proposes to use to determine when medical products that rely on artificial intelligence will require FDA review before being commercialized.

FDA Commissioner Scott Gottlieb is making the most of his final week at the agency. In the month that has passed since Gottlieb rattled the medical device industry with news of his impending resignation, the commissioner has issued 18 public statements pertaining to nearly all corners of the agency's realm, from food, tobacco, and cosmetics to drugs and devices. Friday is Gottlieb's last day on the job. On Tuesday, Gottlieb said the agency will consider a new regulatory framework for reviewing medical devices that use advanced artificial intelligence algorithms. AI has been making headlines in medtech for a while now, and this is certainly not the first time FDA has turned its attention to how AI-based medical devices should be regulated.

In a recent speech at the Bipartisan Policy Center conference, FDA Commissioner, Scott Gottlieb, discussed how the future success of clinical trials will be underpinned by new streams of real world data (RWD). This includes information collected from electronic health records, lab tests, wearable devices, insurance claims and even social media. As he made clear, "digital technologies are one of the most promising tools we have for making health care more efficient and more patient-focused". The FDA believes that these new approaches to collecting data and the utilization of new technology can radically expand the sources of data available. This will offer important evidence on both the product safety and effectiveness in settings and populations that are notably different to those used within approved trials.

A new anonymous texting bot program is aimed at helping children, teenagers and young adults quit using Juuls and other e-cigarettes. Developed by the large anti-smoking and public health non-profit the Truth Initiative, the text-based coaching is being integrated into the group's This Is Quitting and BecomeAnEx online quitting aids. The need for adolescent-focused programs is dire, according to a slew of recent studies and declarations of a youth vaping'epidemic' from the Food and Drug Administration (FDA) and the Surgeon General. FDA Commissioner Gottlieb called for cessation drugs for teens last month, but in the mean time the Truth Initiative's program hopes to help fill that void with text-coaching designed with teens in mind. Truth Initiative's new program texts encouragement geared toward teenagers who are trying to quit vaping in general - but focuses on the addictive Juul in particular Between 2017 and 2018, the number of high school students using e-cigarettes double, according to a University of Michigan study published in December. The rise of vaping was the steepest single-year change documented by the survey in all of its 44 years - a greater increase than has ever been seen in teen drinking, smoking or drug use.